MULTIOMIC BIOMARKER SIGNATURES IDENTIFY SUBSETS OF PATIENTS WHO MAY BENEFIT FROM EITHER NIVOLUMAB OR SOTIGALIMAB IN COMBINATION WITH CHEMOTHERAPY IN METASTATIC PANCREATIC CANCER Maurer, D., Yu, J., Sklodowski, K., Tognetti, M., Reiter, L., Bruderer, R., Vowinckel, J., Pfeiffer, S., O'Hara, M., O'Reilly, E., Wolff, R., Wainberg, Z., Ko, A., Rahm, O., Fisher, G., Lyman, J., Cabanski, C., Gherardini, P., O'Donnell-Tormey, J., LaVallee, T., Vonderheide, R., Kitch, L. BMJ PUBLISHING GROUP. 2021: A370

View details for DOI 10.1136/jitc-2021-SITC2021.343

View details for Web of Science ID 000774877500332